Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating restated by equities researchers at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell in a note issued to investors on Tuesday, Anlyst Ratings reports. They currently have a $108.00 target price on the biotechnology company’s stock, down from their previous target price of $215.00. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell’s target price would indicate a potential upside of 23.82% from the company’s previous close.
Other research analysts also recently issued research reports about the company. Piper Sandler upped their price objective on Sarepta Therapeutics from $200.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, January 4th. UBS Group downgraded Sarepta Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Raymond James downgraded Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, January 8th. Royal Bank of Canada decreased their target price on shares of Sarepta Therapeutics from $200.00 to $143.00 and set an “outperform” rating for the company in a research report on Friday, January 8th. Finally, SVB Leerink decreased their target price on shares of Sarepta Therapeutics from $197.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 8th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and sixteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $160.38.
Sarepta Therapeutics stock opened at $87.22 on Tuesday. The business has a 50 day moving average of $153.98 and a 200-day moving average of $148.77. Sarepta Therapeutics has a 1 year low of $78.06 and a 1 year high of $181.83. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.93 and a quick ratio of 6.42. The company has a market capitalization of $6.88 billion, a P/E ratio of -12.42 and a beta of 1.82.
In related news, insider Joseph Bratica sold 1,115 shares of the stock in a transaction on Friday, December 11th. The stock was sold at an average price of $165.00, for a total value of $183,975.00. Following the transaction, the insider now directly owns 9,255 shares in the company, valued at approximately $1,527,075. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 5.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Pathstone Family Office LLC grew its position in Sarepta Therapeutics by 270.9% in the 3rd quarter. Pathstone Family Office LLC now owns 204 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 149 shares during the period. Private Advisor Group LLC acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at $30,000. Patriot Financial Group Insurance Agency LLC grew its position in Sarepta Therapeutics by 84.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 436 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 200 shares during the period. HM Payson & Co. acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at $76,000. Finally, Pacer Advisors Inc. acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at $93,000. 92.70% of the stock is owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Read More: Fundamental Analysis
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.